Suspension from Quotation
Open PDF
| Stock | NX1.ASX (NX1.ASX) |
|---|---|
| Release Time | 26 May 2026, 10:34 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
NX1.ASX Securities Suspended from Quotation
Key Points
- Securities of Nexalis Therapeutics Ltd (NX1) suspended from quotation
- Suspension requested by NX1 under Listing Rule 17.2
- Suspension pending announcement regarding debt funding facility
- Expected announcement before 28 May 2026
Full Summary
Nexalis Therapeutics Ltd (NX1) has requested a voluntary suspension of its securities from quotation under ASX Listing Rule 17.2. The suspension is necessary to manage continuous disclosure obligations as the company prepares to make an announcement regarding its existing debt funding facility. The suspension will remain in place until the announcement is released or until 28 May 2026, whichever comes first. The company expects to make the announcement before the commencement of normal trading on 28 May 2026.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In